This phenomenon may be attributed to gefitinib-induced paradoxical activation of ERK1/2 in resistant cells through the MSI2-AGO2/miR-30a-3p-CGRRF1 regulatory axis, which subsequently activates the KRAS/ERK pathway to promote tumor progression and drug resistance [53]. Here, KRAS is linked to neoplasm.